Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.507 GBX | -0.97% | -0.45% | -9.46% |
Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 78.7M 98.51M |
---|---|---|---|---|---|
Net income 2024 * | -14M -17.52M | Net income 2025 * | -14M -17.52M | EV / Sales 2024 * | - |
Net Debt 2024 * | 3.88M 4.85M | Net Debt 2025 * | 14.94M 18.71M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.34
x | P/E ratio 2025 * |
-6.35
x | Employees | 51 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.52% |
1 day | -0.97% | ||
1 week | -0.45% | ||
Current month | -7.25% | ||
1 month | -7.25% | ||
3 months | -9.46% | ||
6 months | -30.10% | ||
Current year | -9.46% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Director of Finance/CFO | 38 | 23-08-28 | |
Fayaz Master
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 65 | 23-01-31 | |
Ursula Ney
BRD | Director/Board Member | 72 | 19-10-22 |
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 9.507 | -0.97% | 114 501 |
24-04-24 | 9.6 | 0.00% | 111,474 |
24-04-23 | 9.6 | 0.00% | 319,243 |
24-04-22 | 9.6 | 0.00% | 148,421 |
24-04-19 | 9.6 | +0.52% | 244,525 |
Delayed Quote London S.E., April 25, 2024 at 04:56 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.46% | 97.84M | |
+4.09% | 43.84B | |
+46.51% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- SCLP Stock